clofazimine has been researched along with Pyoderma in 24 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Pyoderma: Any purulent skin disease (Dorland, 27th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five patients suffering from dermatitis ulcerosa (a variant of pyoderma gangrenosum) were treated with clofazimine in a daily dosage of 200 mg orally." | 9.06 | Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial. ( Mensing, H, 1988) |
| "Seven patients with pyoderma gangrenosum have been treated with clofazimine." | 9.05 | Pyoderma gangrenosum treated with clofazimine: clinical evaluation of 7 cases. ( Rasmussen, I, 1983) |
| "Three cases of pyoderma gangrenosum (PG) responsive to clofazimine are reported." | 7.66 | Pyoderma gangrenosum treated with clofazimine. Report of three cases. ( Davis, BR; Kark, EC; Pomeranz, JR, 1981) |
| "A male patient 68 years, suffering from pyoderma gangrenosum which was resistant to conventional treatment, received clofazimine 400 mg daily for 5 months, then reducing to 300 mg daily for the next 6 months." | 7.66 | Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum. ( Chaplin, AJ; Hede, JE; Horsfall, WR; McDougall, AC, 1980) |
| "Ten patients with pyoderma gangrenosum, seven female and three male, 25 to 94 years old, mainly with multiple lesions, have been treated with clofazimine, 100 mg three times daily." | 7.66 | Clofazimine in the treatment of pyoderma gangrenosum. ( Rothenborg, HW; Thomsen, K, 1979) |
| "Two patients with pyoderma gangrenosum have responded remarkably well to treatment with Clofazimine (Lamprène)." | 7.65 | [Pyoderma gangrenosum: Clofazimine therapy]. ( Beurey, J; Chaulieu, Y; Delrous, JL; Weber, M, 1977) |
| "Five patients suffering from dermatitis ulcerosa (a variant of pyoderma gangrenosum) were treated with clofazimine in a daily dosage of 200 mg orally." | 5.06 | Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial. ( Mensing, H, 1988) |
| "Seven patients with pyoderma gangrenosum have been treated with clofazimine." | 5.05 | Pyoderma gangrenosum treated with clofazimine: clinical evaluation of 7 cases. ( Rasmussen, I, 1983) |
| "Clofazimine, a commonly used anti-lepromatous drug, is now being prescribed for the treatment of pyoderma gangrenosum, a complication of inflammatory bowel disease." | 3.68 | Orange/black discolouration of the bowel (at laparotomy) due to clofazimine. ( Farrell, KE; Guli, E; King, RW; Merrett, MN; Zeimer, H, 1990) |
| "Three cases of pyoderma gangrenosum (PG) responsive to clofazimine are reported." | 3.66 | Pyoderma gangrenosum treated with clofazimine. Report of three cases. ( Davis, BR; Kark, EC; Pomeranz, JR, 1981) |
| "A male patient 68 years, suffering from pyoderma gangrenosum which was resistant to conventional treatment, received clofazimine 400 mg daily for 5 months, then reducing to 300 mg daily for the next 6 months." | 3.66 | Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum. ( Chaplin, AJ; Hede, JE; Horsfall, WR; McDougall, AC, 1980) |
| "Two patients with pyoderma gangrenosum have responded remarkably well to treatment with Clofazimine (Lamprène)." | 3.65 | [Pyoderma gangrenosum: Clofazimine therapy]. ( Beurey, J; Chaulieu, Y; Delrous, JL; Weber, M, 1977) |
| "Treatment with prednisolone and clofazimine produced an excellent clinical response." | 1.27 | Pyoderma gangrenosum associated with selective hereditary IgA deficiency. ( Bundino, S; Zina, AM, 1984) |
| "Treatment with clofazimine resulted in a marked improvement of the lesions." | 1.27 | Malignant pyoderma. Report of a case associated with a disorder of the immune system. ( Aram, H, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (91.67) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rasmussen, I | 1 |
| Beurey, J | 2 |
| Weber, M | 2 |
| Chaulieu, Y | 2 |
| Murray, JC | 1 |
| Bundino, S | 1 |
| Zina, AM | 1 |
| De Maubeuge, J | 1 |
| Ledoux, M | 1 |
| Duchateau, J | 1 |
| Schell, E | 1 |
| Achten, G | 1 |
| Bentley-Phillips, CB | 1 |
| Cooper, RC | 1 |
| Hallett, AF | 1 |
| Chavaz, P | 1 |
| Laugier, P | 1 |
| Kark, EC | 1 |
| Davis, BR | 1 |
| Pomeranz, JR | 1 |
| Cola, B | 1 |
| Porzio, F | 1 |
| Farella, S | 1 |
| Lovett, GW | 1 |
| Field, JP | 1 |
| King, LE | 1 |
| Ohela, K | 1 |
| McDougall, AC | 1 |
| Horsfall, WR | 1 |
| Hede, JE | 1 |
| Chaplin, AJ | 1 |
| Thomsen, K | 1 |
| Rothenborg, HW | 1 |
| Delrous, JL | 1 |
| Brandt, L | 1 |
| Gärtner, I | 1 |
| Nilsson, PG | 1 |
| Olofsson, T | 1 |
| Michaëlsson, G | 1 |
| Molin, L | 1 |
| Ohmann, S | 1 |
| Gip, L | 1 |
| Lindström, B | 1 |
| Skogh, M | 1 |
| Trolin, I | 1 |
| Stone, OJ | 1 |
| Merrett, MN | 1 |
| King, RW | 1 |
| Farrell, KE | 1 |
| Zeimer, H | 1 |
| Guli, E | 1 |
| Grob, JJ | 1 |
| Mège, JL | 2 |
| Collet-Villette, AM | 1 |
| Bonerandi, JJ | 1 |
| Mensing, H | 1 |
| Berbis, P | 1 |
| Capo, C | 1 |
| Kaplanski, S | 1 |
| Bongrand, P | 1 |
| Privat, Y | 1 |
| Aram, H | 2 |
| Read, AE | 1 |
2 reviews available for clofazimine and Pyoderma
| Article | Year |
|---|---|
[Lamprène. New therapeutic indications (excluding leprosy)].
Topics: Acne Vulgaris; Adult; Clofazimine; Female; Humans; Lupus Erythematosus, Discoid; Lupus Vulgaris; Mal | 1982 |
Pyoderma gangrenosum with IgA gammopathy.
Topics: Arthritis; Clofazimine; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypergammaglobuline | 1983 |
2 trials available for clofazimine and Pyoderma
| Article | Year |
|---|---|
Pyoderma gangrenosum treated with clofazimine: clinical evaluation of 7 cases.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Clofazimine; Female; Humans; Male; Middle Ag | 1983 |
Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial.
Topics: Adult; Aged; Clinical Trials as Topic; Clofazimine; Female; Gangrene; Humans; Male; Middle Aged; Pyo | 1988 |
20 other studies available for clofazimine and Pyoderma
| Article | Year |
|---|---|
Pyoderma gangrenosum associated with selective hereditary IgA deficiency.
Topics: Child, Preschool; Clofazimine; Female; Gangrene; Humans; IgA Deficiency; Prednisolone; Pyoderma; Ski | 1984 |
[Pyoderma gangrenosum: 2 cases treated with lamprene. Immunologic study].
Topics: Adult; Clofazimine; Female; Humans; Middle Aged; Pyoderma; T-Lymphocytes | 1982 |
Pharmacological modulation of neutrophil phagocytic function in a patient with recurrent sepsis, pyoderma gangrenosum and impaired phagocytosis.
Topics: Adrenal Cortex Hormones; Bacterial Infections; Clofazimine; Humans; In Vitro Techniques; Levamisole; | 1982 |
[Use of lamprène in dermatology].
Topics: Aged; Clofazimine; Humans; Pyoderma; Skin Ulcer | 1982 |
Pyoderma gangrenosum treated with clofazimine. Report of three cases.
Topics: Chronic Disease; Clofazimine; Female; Humans; Male; Middle Aged; Pyoderma; Skin Ulcer; Wound Healing | 1981 |
[Pyoderma gangrenosum: 2 cases with perineal localization].
Topics: Aged; Clofazimine; Female; Gangrene; Humans; Middle Aged; Perineum; Pyoderma; Skin Ulcer | 1980 |
Treatment of pyoderma gangrenosum with clofazimine. A case report and review of associated diseases.
Topics: Clofazimine; Diagnosis, Differential; Female; Gangrene; Humans; Middle Aged; Pyoderma | 1981 |
[Pyoderma gangrenosum treated with prednisolone and clofazimine].
Topics: Adult; Clofazimine; Female; Gangrene; Humans; Prednisolone; Pyoderma | 1981 |
Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum.
Topics: Aged; Clofazimine; Humans; Lymph Nodes; Male; Mesentery; Pyoderma; Skin Ulcer; Splenic Infarction | 1980 |
Clofazimine in the treatment of pyoderma gangrenosum.
Topics: Adult; Aged; Clofazimine; Female; Humans; Male; Middle Aged; Pyoderma | 1979 |
[Pyoderma gangrenosum: Clofazimine therapy].
Topics: Adult; Aged; Clofazimine; Female; Gangrene; Humans; Immunity, Cellular; Pyoderma | 1977 |
Pyoderma gangrenosum associated with regional enteritis. Improvement in defective granulocyte function and healing of skin lesions during administration of clofazimine.
Topics: Adult; Clofazimine; Crohn Disease; Female; Granulocytes; Humans; Oxygen Consumption; Phagocyte Bacte | 1977 |
Clofazimine. A new agent for the treatment of pyoderma gangrenosum.
Topics: Adult; Aged; Clofazimine; Drug Evaluation; Female; Gangrene; Humans; Male; Middle Aged; Pyoderma | 1976 |
Sulfapyridine and sulfones decrease glycosaminoglycans viscosity in dermatitis herpetiformis, ulcerative colitis, and pyoderma gangrenosum.
Topics: Clofazimine; Colitis, Ulcerative; Dermatitis Herpetiformis; Glycosaminoglycans; Humans; Leprosy; Pyo | 1990 |
Orange/black discolouration of the bowel (at laparotomy) due to clofazimine.
Topics: Adult; Clofazimine; Crohn Disease; Female; Humans; Ileum; Pyoderma | 1990 |
[Dermatitis ulcerosa or superficial granulomatous pyoderma. Functional abnormalities of the neutrophils and transient efficacy of clofazimine].
Topics: Aged; Clofazimine; Humans; Male; Neutrophils; Pyoderma | 1989 |
Hyperimmunoglobulin E and impaired neutrophil functions in a case of pyoderma gangrenosum: effect of clofazimine.
Topics: Adult; Clofazimine; Humans; Hypergammaglobulinemia; Immunoglobulin E; Male; Neutrophils; Pyoderma; S | 1988 |
Malignant pyoderma.
Topics: Adult; Clofazimine; Humans; Male; Pyoderma | 1987 |
Pyoderma gangrenosum.
Topics: Arthritis; Clofazimine; Colitis, Ulcerative; Crohn Disease; Humans; Male; Pyoderma | 1985 |
Malignant pyoderma. Report of a case associated with a disorder of the immune system.
Topics: Adult; Clofazimine; Diagnosis, Differential; Humans; Immune System Diseases; Male; Middle Aged; Pyod | 1985 |